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DOI 10.1186/s12863-014-0136-1RESEARCH ARTICLE Open AccessChromosome 16q22 variants in a region
associated with cardiovascular phenotypes
correlate with ZFHX3 expression in a
transcript-specific manner
Ruairidh I R Martin1, W Andrew Owens1,2, Michael S Cunnington1,3, Bongani M Mayosi4,
Mauro Santibáñez Koref1 and Bernard D Keavney1,5*Abstract
Background: The ZFHX3 gene, located in Chromosome 16q22.3, codes for a transcription factor which is widely
expressed in human tissues. Genome-wide studies have identified associations between variants within the gene
and Kawasaki disease and atrial fibrillation. ZFHX3 has two main transcripts that utilise different transcription start
sites. We examined the association between genetic variants in the 16q22.3 region and expression of ZFHX3 to
identify variants that regulate gene expression.
Results: We genotyped 65 single-nucleotide polymorphisms to tag genetic variation at the ZFHX3 locus in two
cohorts, 451 British individuals recruited in the North East of England and 310 mixed-ancestry individuals recruited
in South Africa. Allelic expression analysis revealed that the minor (A) allele of rs8060701, a variant in the first intron
of ZFHX3, was associated with a 1.16-fold decrease in allelic expression of both transcripts together, (p = 4.87e-06).
The minor (C) allele of a transcribed variant, rs10852515, in the second exon of ZFHX3 isoform A was independently
associated with a 1.36-fold decrease in allelic expression of ZFHX3 A (p = 7.06e-31), but not overall ZFHX3 expression.
However, analysis of total gene expression of ZFHX3 failed to detect an association with genotype at any variant.
Differences in linkage disequilibrium between the two populations allowed fine-mapping of the locus to a 7 kb
region overlapping exon 2 of ZFHX3 A. We did not find any association between ZFHX3 expression and any of the
variants identified by genome wide association studies.
Conclusions: ZFHX3 transcription is regulated in a transcript-specific fashion by independent cis-acting transcribed
polymorphisms. Our results demonstrate the power of allelic expression analysis and trans-ethnic fine mapping to
identify transcript-specific cis-acting regulatory elements.
Keywords: Expression QTL mapping, Trans-ethnic mapping, Atrial fibrillation, Genome-wide association studyBackground
The chromosome 16q22.3 region contains the locus en-
coding the zinc-finger homeobox protein ZFHX3 and
has been shown to be associated with susceptibility to
several cardiovascular disease phenotypes. Genome-wide
association studies (GWAS) have identified associations
between single-nucleotide polymorphisms (SNPs) in this
region and atrial fibrillation (AF) [1-3], Kawasaki disease* Correspondence: bernard.keavney@manchester.ac.uk
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unless otherwise stated.[4] and cardioembolic stroke [2,5]. The variants identi-
fied by GWAS are outside coding regions and so the as-
sociations are almost certainly mediated by influences
on gene expression. Variants associated with cardiovas-
cular disease span a region of 43 kb within the first in-
tron of ZFHX3.
ZFHX3, formerly known as ATFB1, is the only
protein-coding gene within 500 kb of the GWAS hit
SNPs. ZFHX3 codes for a transcription factor (TF)
which is widely expressed and is reported in all 16 tis-
sues covered by the Body Map 2.0 project [6]. There areThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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two transcripts have different promoter regions [7].
The ZFHX3 A transcript differs from the B isoform by
the addition of 420 amino acids at the N-terminus (see
Figure 1). Absence of ZFHX3 expression and mutations
near the ATP binding domain are associated with an in-
crease in malignant activity in hepatocellular, gastric,
breast and prostate carcinoma [8-11].
We have previously shown that the power of expres-
sion quantitative trait locus (eQTL) mapping using total
levels of gene expression may be significantly limited
by variation in trans acting factors such as age, gen-
der or drugs. An alternative approach, which is specific
for cis acting eQTLs, is to analyse relative expression of
the two alleles of a transcript (allelic expression [aeQTL]
mapping). Because both alleles are affected by trans acting
influences such as age, disease status, medication etc., the
allelic expression ratio (AER) is largely independent of
them. We and others have shown that aeQTL mapping
has a greater power to detect cis acting elements than
eQTL mapping [12-14]. However, aeQTL mapping relies
on there being one or more transcribed polymorphisms
in a heterozygous state to determine the allelic origin of
the transcripts.
The evidence for cis-acting eQTLs elements in ZFHX3
thus far is conflicting. Associations between variants in
the region, including GWAS hit SNPs, and gene expres-
sion have not been consistently identified in lymphoblas-
toid cell lines (LCLs) and no associations have been
reported in primary tissues [15-17].
We used eQTL and aeQTL mapping to perform de-
tailed fine-mapping of the association of SNPs at the
16q22.3 locus with expression of ZFHX3. We used DNA
and RNA collected from peripheral blood cells in two
cohorts of individuals recruited in the north-east of
England (NE cohort) and South Africa (SA cohort).
We identified multiple SNPs associated with allelic
expression of ZFHX3 whose effects were specific for
each transcript.Figure 1 ZFHX3 protein domains. There are a large number of zinc finge
acids unique to ZFHX3 A, there is a DEAD-like and a DEAH-like domain and
SNPs rs10852515 and rs740178 are indicated by arrows.Methods
Participants
Peripheral blood for DNA and RNA analysis was col-
lected from anonymous adult volunteers in two cohorts:
310 South African mixed-ancestry blood donors and 451
hospital patients from north-east England. Of the NE
cohort, 401 individuals were recruited at the time of car-
diac catheterisation and 50 at the time of cardiac sur-
gery. 66% were male and the median age was 68 years
(range 22-88, lower quartile 59, upper quartile 74). Of
the SA cohort 42% were male, with median age 20 years
(range 17–60, lower quartile 19, upper quartile 23) [12].
Ethics statement
The study complies with the Declaration of Helsinki. In-
formed consent was obtained from all participants and the
study was approved by the Sunderland Local Research
Ethics Committee and the University of Cape Town
Faculty of Health Sciences Research Ethics Committee.
Selection of transcribed SNPs for allelic expression analysis
Using the UCSC genome browser [18,19] transcribed SNPs
with minor allele frequency (MAF) >0.05 were identified
as suitable candidates for use in the allelic expression
assays. Transcribed SNPs selected using these criteria
were rs740178, in exon 8 of ZFHX3 A and exon 7 of
ZFHX3 B, and rs10852515 in exon 2 of ZFHX3 A. There
was no reported transcribed SNP which was specific for
ZFHX3 B. Measurement of the allelic expression ratio
(AER) using rs740178 allows assessment of both tran-
scripts taken together. rs10852515 is not present in the
spliced ZFHX3 B transcript and so measurement using
rs10852515 allows assessment of the AER in ZFHX3 A
alone (Figure 1).
Selection of mapping SNPs
The lead GWAS hit SNP for Kawasaki disease is not in
strong linkage disequilibrium (LD) with the AF hit SNPs,
which are in strong LD with each other (Additional file 1:r and four homeobox nucleic acid binding domains. In the 915 amino
an RNA binding motif. The positions of the transcribed synonymous
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ation in a core region of interest (Chr16: 72,801,786-
73,107,534) based on HapMap CEU data were selected
using HaploView 4.0 tagger software. We used the follow-
ing parameters: minimum minor allele frequency 0.05,
pairwise tagging, r2 threshold >0.8. SNPs previously
reported to be associated with disease phenotypes were
force-included in the SNP selection process [1-4,20].
Details of included SNPs are shown in Additional file 1:
Tables S2-S4.
Genotyping and measurement of expression
Genotyping and measurement of allelic expression ratios
was performed by MALDI-TOF mass spectrometry
(Sequenom). Total gene expression was measured using
real-time PCR, according to MIQE guidelines [21]. Full
details are included in the supplementary methods.
Statistical analyses
The association between total expression, as measured by
real time PCR, and each of the SNPs was assessed using
linear regression of the log transformed normalised ex-
pression values on the genotype, assuming no dominance
or interactions between the effects of different SNPs. PCR
plate was included as a categorical variable.
Genotype phase was estimated for each cohort separ-
ately using the BEAGLE v3.3.2 Genetic Analysis Software
Package [22]. LD was calculated using phased genotypes
in HaploView v4.2 and haplotype blocks were identified
using the confidence interval algorithm [23,24]. We ana-
lysed allelic expression ratios and estimated the propor-
tion of variance that was due to cis-acting effects using the
approaches that we published previously [12]. The ana-
lyses in the NE cohort were replicated in the SA cohort
and the results compared to allow trans-ethnic fine map-
ping of associations. In order to provide increased power,
the results from each cohort were meta-analysed using
Fisher’s method.
For both total and allelic expression multiple testing, cor-
rected p-values were calculated as the family-wise error rate
(FWER) using Holm’s correction for the 65 SNPs tested.
Holm’s procedure is more efficient than the Bonferroni
method of correction for multiple association testing and
so is less conservative, without an increase in type I error
[25]. Associations with a corrected p-value below a thresh-
old of 0.05 were considered significant. From our allelic
and total expression data we also estimated the proportion
of the total expression variance that is due to cis-acting ef-
fects using previously published methods [12].
Results
After quality control, we measured total expression of
ZFHX3 in peripheral blood from 366 individuals in the
NE cohort. Allelic expression was assessed for bothtranscripts taken together using the transcribed SNP
rs740178 in 132 individuals in both cohorts and for the A
transcript alone using the transcribed SNP rs10852515
in 152 individuals in both cohorts. We selected 65 SNPs
that tag the common variation in the region, specifically
including SNPs with previously reported phenotypic
associations. The results of allelic expression mapping
were compared with conventional mapping using total
expression in the samples. The results are summarised in
Additional file 1: Tables S2-S4.
Inter-individual variation in expression
Total ZFHX3 expression levels between individuals
varied up to 9.64-fold. Expression ratios at individual
transcribed markers also showed inter-individual vari-
ation, the range of the ratio of the minor:major alleles
was 0.71:1– 1.65:1 for both transcripts taken together
and 0.39:1– 1.48:1 for transcript A alone, indicating
that ZFHX3 expression is regulated by factors which differ
between individuals and that there was greater inter-
individual variability in the AER of transcript A. Plots of
the log allelic expression ratios and log2 total expression
values for each individual are shown in Additional file 1:
Figure S1. We estimated 3.7% of the variance to be due to
cis-acting effects.
Analysis of total expression
No significant associations were detected between SNP
genotype and total expression of ZFHX3 in the NE cohort,
as assessed by qPCR (Figure 2 and Additional file 1:
Table S2). As no associations were seen replication was
not performed in the SA cohort.
Comparison of patterns of linkage disequilibrium
between populations
Patterns of LD in the two populations are shown in
Additional file 1: Figure S2. The pattern of LD and the
haplotype blocks differed significantly between the two
populations. We analysed aeQTLs in both populations
separately to determine the effects of different popula-
tion haplotype structures on aeQTLs. We subsequently
performed a meta analysis of the results in both cohorts,
increasing the power to detect smaller cis-acting effects.
Raw and corrected p values are shown in Additional file 1:
Tables S3 and S4.
Analysis of allelic expression of both A and B transcripts
aeQTL mapping of both transcripts together identified a
single significantly associated SNP, rs8060701 in the NE
cohort (p = 1.29e-04) (Additional file 1: Table S3). This
was replicated in the SA cohort (p = 2.82e-03). When
both data sets were combined, the minor (A) allele was
associated with a 1.17-fold decrease in expression of
both ZFHX3 transcripts combined (p = 4.87e-06, corrected
Figure 2 Associations between SNP genotype and gene expression. SNPs are plotted with chromosomal position on the x axis and –log p
value on the y axis. The horizontal line represents the significance threshold (p = 0.05). Individual points are coloured to indicate effect size (β).
No SNP is significantly associated with whole gene expression. A single SNP, rs8060701, is significantly associated with allelic expression of both
transcripts together. 11 SNPs are associated with allelic expression of the A transcript. The cartoon at top shows the position of transcripts A and
B of ZFHX3. Both isoforms are transcribed in the reverse direction, arrow.
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no further associations were seen in any cohort.
Analysis of allelic expression of ZFHX3 A
aeQTL mapping of transcript A in the NE cohort re-
vealed several strongly associated SNPs (Figure 2 and
Additional file 1: Table S4). The most strongly associated
SNP was the transcribed SNP, rs10852515 (p = 7.47e-15).
This association was strongly replicated in the SA cohort
(p = 1.12e-16). In the combined data set, the minor (C)
allele was associated with a 1.35-fold decrease in ZFHX3
A expression (p = 9.61e-31, corrected p = 6.25e-29). After
correction for the effects of rs10852515, no other vari-
ants were independently associated with expression. The
aeQTL SNP associated with expression of both tran-
scripts, rs8060701, was not independently associated with
ZFHX3 A expression, rs10852515 and rs8060701 were not
in significant LD in the SA cohort (r2 = 0) or the NE co-
hort (r2 = 0.005).
The pattern of association between ZFHX3 A expres-
sion and SNP genotype differed between the two popula-
tions. After correction for multiple testing, the aeQTL in
the NE cohort included 12 significantly associated SNPs
in a 93 kb region. By contrast, in the SA cohort the aeQTL
was confined to three SNPs in a 7 kb region (Figure 3). In
both cohorts, the significantly associated variants werein LD with the SNP with the most significant p-value,
rs10852515. The log p value for the association was sig-
nificantly associated with the degree of LD (r2) with
rs10852515 in both cohorts, confirming that the dif-
ferences between associations in the two cohorts were
a result of differing patterns of LD (Additional file 1:
Figure S3).Associations between GWAS significant variants and
ZFHX3 expression
The Kawasaki disease-associated SNP, rs7199343 and the
AF-associated SNPs rs7193373 and rs2106261 were
not significantly associated with ZFHX3 A expression
(corrected p > 0.05 in all cases).Discussion
We have shown that multiple SNPs in the ZFHX3 region
are significantly associated with ZFHX3 expression in
whole blood in a transcript specific manner. We have iden-
tified an aeQTL regulating ZFHX3 isoform A expression,
demonstrating that allelic expression analysis is a powerful
approach to investigation of transcript-specific gene ex-
pression. Additionally we have confirmed in peripheral
blood the association between rs8060701 and expression
of both transcripts in LCLs; this is the first demonstration
Figure 3 Comparison of results for ZFHX3 A expression in the SA and NE cohorts. SNPs are plotted with chromosomal position on the x
axis and strength of association n the y axis. Colour indicates effect size. Results from the NE and SA cohorts are shown as squares and triangles
respectively. The regions of significant association with ZFHX3 A expression in each cohort are shown as black bars.
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human tissue.
Expression levels of ZFHX3 vary significantly between
individuals and cis-acting factors account for only 3.7%
of that variance. ZFHX3 is involved in the cellular re-
sponse to genotoxic and oxidative stress [26] and its ex-
pression is known to be influenced by a large number of
trans acting factors, including cytokine levels, viral infec-
tion, tissue injury and drug treatment [27].
A number of SNPs were associated with ZFHX3 expres-
sion. However after correcting for the effect of rs10852515,
no other significant associations remained, which is con-
sistent with the transcribed SNP itself being either the
functional SNP or in strong LD with an untyped functional
SNP. The use of the Cape mixed-ancestry cohort allowed
much finer localisation of the aeQTL from a 93 kb to a
7 kb region. This study therefore demonstrates the power
of trans-ethnic fine mapping combined with allelic expres-
sion analysis to fine-map aeQTLs within regions associated
with gene expression.
In the lymphoblastoid cell line (LCL) arm of the MuTHER
study, a microarray-based genome-wide analysis of gene
expression in skin, adipose tissue and LCLs in a cohort of
UK twins, an association was found between rs8060701
and ZFHX3 expression (n = 856, p = 8.27e-05) [16,28].Figure 4 The ZFHX3 locus. Refseq genes within 1 MB of the identified GW
protein-coding genes which extends 800 Mb from the risk polymorphismsThis association was not found in the tissue arms of the
MuTHER study or in the GenCord study but has been
demonstrated here. Our findings, therefore, confirm that
this association is present in primary human tissue. The
Illumina probe used in the MuTHER and GenCord stud-
ies is not transcript-specific and so would not have
allowed detection of transcript-specific eQTLs.
Changes in the relative expression of the two isoforms
of ZFHX3 has been shown to determine the rate of
differentiation of C2C12 myoblasts, the B transcript accel-
erating myogenic differentiation and the A isoform result-
ing in persistence of an undifferentiated phenotype
[29]. This suggests that transcript-specific regulation of
ZFHX3 expression may have an important role in control
of differentiation and cellular proliferation. Transcript-
specific regulation of gene expression has been associated
with other diseases including schizophrenia, affective dis-
orders and hepatocellular carcinoma [30,31].
We found no association between ZFHX3 expression and
genotype at those SNPs associated with Kawasaki disease
or AF. ZFHX3 was selected as a candidate gene for the
mechanism of action of the GWAS hit SNPs as the lead
SNPs lie in the first intron of the gene and no other genes
lie in the region of association. It is possible, however, that
the mechanism of action of these SNPs is mediated throughAS SNPs are shown. There is a large region with relatively few
, highlighting the relevance of ZFHX3 as a candidate gene.
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of association is that the effects of the GWAS lead SNPs on
gene expression are tissue specific and that there are cis-
acting eQTLs in atrial or other disease-relevant tissues that
are not active in peripheral blood.
Limitations
Our results demonstrate that the SNPs rs8060701 and
rs10852515 are associated with ZFHX3 expression. From
our data, however, it is not possible to determine whether
the lead SNPs are the functional variants or are simply in
strong LD with the true functional variants. Further stud-
ies are required to identify the exact mechanisms by which
the variants regulate expression. We found no association
between the GWAS hit SNPs at this locus and ZFHX3
expression. As there are very few other genes in this
region that might be responsible for the GWAS asso-
ciations (Figure 4), it is possible that there are eQTLs
for ZFHX3 in other tissues that we have been unable
to detect in peripheral blood.
Conclusions
We have identified two independent cis-acting regulatory
elements in ZFHX3 which act in a transcript-specific
fashion. We have discovered a transcribed polymorph-
ism which regulates ZFHX3 isoform A expression,
using trans-ethnic fine mapping to localise the func-
tional SNP. We have also confirmed that variants in the
first intron of ZFHX3 that are associated with overall
ZFHX3 expression in LCLs are also associated with ex-
pression in peripheral blood. These findings confirm the
increased power of the aeQTL approach over eQTL
mapping to identify cis-acting variants and additionally
demonstrate the usefulness of this technique in identify-
ing transcript-specific regulatory elements.
Additional file
Additional file 1: Supplementary Methods and Results.
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